Cash generation came in above the company’s own near-term bar. Portfolio Receipts of $773 million exceeded the $740 million–$760 million range communicated before the quarter by $13 million–$33 million, while Royalty Receipts rose 14%. That is the cleaner operating read for this royalty business than GAAP net income, which moved sharply with non-cash expected-cash-flow provisions and R&D funding expense. (Portfolio Receipts by product table; Condensed Consolidated Statements of Operations)
| Metric | Q2 2026 | Q2 2025 | Standing expectation / prior outlook |
|---|---|---|---|
| Portfolio Receipts | $773m | $727m (+6%) | $740m–$760m for Q2 (Guidance; Portfolio Receipts highlights) |
| Royalty Receipts | $768m | $672m (+14%) | — (Portfolio Receipts by product table) |
| Adjusted EBITDA | $736m | $633m (+16%) | — (Adjusted EBITDA and Portfolio Cash Flow table) |
| Portfolio Cash Flow | $736m | $641m (+15%) | — (Adjusted EBITDA and Portfolio Cash Flow table) |
| Net cash from operating activities | $728m | $364m (+100%) | — (Condensed Consolidated Statements of Cash Flows) |
| 2026 Portfolio Receipts guidance | $3.40bn–$3.50bn | — | Raised from $3.325bn–$3.45bn (2026 Guidance) |
The full-year upgrade validates the beat, but it is incremental rather than a reset. The new $3.40 billion–$3.50 billion Portfolio Receipts range lifts the midpoint by $62.5 million, or about 2%, and raises expected Royalty Receipts growth to 7%–10% from 4%–8% previously. The upper end is only $50 million higher, so the filing supports a modestly stronger 2026 cash-receipts outlook—not a dramatic change in long-term earnings power. (2026 Guidance)
Growth was broad enough to offset known pressure points. Tremfya, Voranigo, Evrysdi, Imdelltra and Trodelvy drove gains, while Promacta fell 75% amid U.S. generic competition and Imbruvica declined 16%. The flat cystic-fibrosis franchise also shows the quarter was not dependent on its largest receipt stream. That diversification is constructive, though several fastest-growing contributors remain smaller than the mature franchises. (Portfolio Receipts by product table)
Cash conversion improved materially after internalization, preserving deployment capacity. Operating and professional costs fell to 4.8% of Portfolio Receipts from 12.9% a year earlier, helping Portfolio Cash Flow rise 15% despite heavier interest payments earlier in the year. The company also repaid its $380 million term loan in July, but still carried $9.2 billion of principal debt at June 30; the improved cash flow helps, rather than eliminates, that leverage consideration. (Adjusted EBITDA and Portfolio Cash Flow table; Balance Sheet; 2026 Guidance)
Pipeline milestones add optionality but were largely already public by this filing. Recent regulatory progress for daraxonrasib, Jideytro, Trodelvy and Imdelltra supports the development portfolio, while Trodelvy’s discontinued lung-cancer combination trial is a counterweight. These updates matter more for future royalty potential than for the quarter’s receipts, and the filing does not quantify their eventual contribution. (Recent portfolio developments)
Read the original 8-K on SEC EDGAR ↗